| Attribute |
Value |
| 52 Week Change |
-0.5 |
| Address1 |
3,710 - 33rd Street NW |
| All Time High |
2,478.6 |
| All Time Low |
1.725 |
| Ask |
2.66 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
10,470 |
| Average Daily Volume3 Month |
1,249,870 |
| Average Volume |
1,249,870 |
| Average Volume10Days |
10,470 |
| Beta |
0.168 |
| Bid |
1.47 |
| Bid Size |
2 |
| Book Value |
0.922 |
| City |
Calgary |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
Canada |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
2.03 |
| Current Ratio |
0.865 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
2.1243 |
| Day Low |
2.03 |
| Debt To Equity |
1.173 |
| Display Name |
XORTX Therapeutics |
| Earnings Timestamp |
1,778,934,600 |
| Earnings Timestamp End |
1,786,624,200 |
| Earnings Timestamp Start |
1,786,624,200 |
| Ebitda |
-2,420,447 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
-1.071 |
| Enterprise Value |
2,591,442 |
| Eps Forward |
0.8018253 |
| Eps Trailing Twelve Months |
-2.45 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
2.31498 |
| Fifty Day Average Change |
-0.28498006 |
| Fifty Day Average Change Percent |
-0.1231026 |
| Fifty Two Week Change Percent |
-50.0 |
| Fifty Two Week High |
7.05 |
| Fifty Two Week High Change |
-5.0200005 |
| Fifty Two Week High Change Percent |
-0.71205676 |
| Fifty Two Week Low |
1.725 |
| Fifty Two Week Low Change |
0.30499995 |
| Fifty Two Week Low Change Percent |
0.17681156 |
| Fifty Two Week Range |
1.725 - 7.05 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,632,403,800,000 |
| Float Shares |
1,370,541 |
| Forward Eps |
0.8018253 |
| Forward P E |
2.5317235 |
| Free Cashflow |
-1,619,871 |
| Full Exchange Name |
NasdaqCM |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.08224 |
| Held Percent Institutions |
0.022349998 |
| Implied Shares Outstanding |
1,730,565 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-10-13 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,775,433,600 |
| Last Split Factor |
1:5 |
| Long Business Summary |
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada. |
| Long Name |
XORTX Therapeutics Inc. |
| Market |
us_market |
| Market Cap |
3,513,047 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_259860883 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-2,766,103 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
3,510,619 |
| Open |
2.11 |
| Operating Cashflow |
-2,626,355 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
403-455-7727 |
| Previous Close |
2.175 |
| Price Hint |
4 |
| Price To Book |
2.2017353 |
| Profit Margins |
0.0 |
| Quick Ratio |
0.366 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
-0.145 |
| Regular Market Change Percent |
-6.66667 |
| Regular Market Day High |
2.1243 |
| Regular Market Day Low |
2.03 |
| Regular Market Day Range |
2.03 - 2.1243 |
| Regular Market Open |
2.11 |
| Regular Market Previous Close |
2.175 |
| Regular Market Price |
2.03 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
13,135 |
| Return On Assets |
-0.53815 |
| Return On Equity |
-1.37442 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
1,730,565 |
| Shares Percent Shares Out |
0.0145000005 |
| Shares Short |
25,044 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
22,256 |
| Short Name |
XORTX Therapeutics Inc. |
| Short Percent Of Float |
0.0147 |
| Short Ratio |
1.57 |
| Source Interval |
15 |
| State |
AB |
| Symbol |
XRTX |
| Total Cash |
250,275 |
| Total Cash Per Share |
0.18 |
| Total Debt |
15,056 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.45 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
2.710595 |
| Two Hundred Day Average Change |
-0.6805949 |
| Two Hundred Day Average Change Percent |
-0.25108692 |
| Type Disp |
Equity |
| Volume |
13,135 |
| Website |
https://www.xortx.com |
| Zip |
T2L 2M1 |